

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT COMPLETION OF ENROLLMENT FOR MULTI-CENTER CLINICAL TRIAL OF MONA LISA PROSTATE PUNCTURE ROBOT

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is hereby pleased to announce that, iSR’obotTM Mona Lisa Robotic Transperineal Prostate Biopsy System (“**Mona Lisa**”), a product of Shanghai Intbot Robotics Co., Ltd. (“**Shanghai Intbot**”), a joint venture company in China jointly established by the Company and Biobot Surgical Pte. Ltd., has completed enrollment for the registrational clinical trials. Nanjing Drum Tower Hospital (the Affiliated Hospital of Nanjing University Medical School) led the clinical trial, with the participation of The First Affiliated Hospital of Xi’an Jiaotong University and Northern Jiangsu People’s Hospital. Mona Lisa operated stably and safely and processed smoothly during the surgeries, with obvious advantages in terms of safety of surgeries, learning curves and the detection rate of punctures as compared with manual punctures in traditional surgeries, which is proved to have significant clinical value.

ABOUT MONA LISA

Mona Lisa is an innovative robotics product in the field of percutaneous puncture, aiming at assisting physicians to complete prostate puncture biopsy surgeries in a safer, more accurate, intelligent and efficient manner. Leveraging on surgical robots and artificial intelligence technology, Mona Lisa can help clinical physicians complete various operations in a better way through intelligent software formulation plan. Mona Lisa not only demonstrates the 3D visualized MRI-ultrasound fusion technology, but its motion compensation and needle offset position compensation technology also enhances the precision of puncture surgeries, so as to reduce the omission diagnostic rate, number of incisions and pain to patients.

IMPACT ON AND SIGNIFICANCE TO THE COMPANY

With the completion of this clinical enrollment, Mona Lisa has become the first prostate puncture robot completing enrollment for registrational clinical trials in the field of urology in China, while it is also a new breakthrough of the Company in the field of percutaneous puncture, indicating a major step for the accurate diagnosis of prostate cancer. Shanghai Intbot plans to submit the registration application of Mona Lisa to the National Medical Products Administration in the third quarter of 2022.

The Company cannot guarantee that Mona Lisa will be developed or ultimately marketed successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board of Directors
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 2 May 2022

As at the date of this announcement, the executive director of the Company is Dr. He Chao, the non-executive directors of the Company are Mr. Sun Hongbin, Mr. Sun Xin and Mr. Chen Chen, and the independent non-executive directors of the Company are Ms. Lee Kit Ying, Dr. Li Minghua and Mr. Yao Haisong.